Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A
开发耐受性因子 VIII 作为免疫疗法来预防 A 型血友病抑制剂的产生
基本信息
- 批准号:10594819
- 负责人:
- 金额:$ 57.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-27 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAntibodiesAntibody titer measurementAutoimmune DiseasesBiologicalBlood Coagulation DisordersBlood coagulationCanis familiarisClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplicationDevelopmentExogenous FactorsFactor VIIIFoundationsFunctional disorderHalf-LifeHealthHemophilia AHemorrhageHemostatic AgentsHumanHypersensitivityImmune responseImmunizationImmunotherapyIntravenousInvestigational DrugsKnowledgeLaboratoriesLifeLipid BindingMeasurableMeasuresMedicalMissionModelingMorbidity - disease rateMusNational Heart, Lung, and Blood InstituteNorth CarolinaOralOutcomePatient CarePatientsPharmaceutical PreparationsPhasePhosphatidylserinesPlasmaPreventionPreventive therapyPrimatesPropertyProteinsProtocols documentationPublic HealthReplacement TherapyResearchRiskRouteSafetyStudy modelsTestingTherapeuticToxic effectTranslatingTreatment ProtocolsUnited States National Institutes of HealthUniversitiescostcost effectiveefficacy evaluationgene therapyhigh riskimmunogenicimmunogenicityimprovedinhibitorinnovationintravenous administrationlysophosphatidylserinemortalitynanoparticlenonhuman primatenovelpharmacokinetics and pharmacodynamicspreservationpreventrecombinant antihemophilic factor VIIIresponsesuccesstechnology platformtherapeutic protein
项目摘要
Hemophilia A (HA) is a bleeding disorder caused by deficiency or dysfunction of Factor VIII (FVIII), an important
blood coagulation protein. The replacement therapy using exogenous FVIII is the first line of therapy. However,
a major clinical complication of this life-saving therapy is the development of neutralizing anti-FVIII antibodies,
referred to as inhibitors, that abrogates the biological activity of FVIII and increases the risk of bleeding related
morbidity and mortality in HA patients. Current clinical options after inhibitor development are costly (>$700,000
per patient annually) and in some patients, ineffective. Thus, prevention of inhibitor development is cost-effective
in terms of patient care but there are no safe and effective preventive therapy currently available to avoid inhibitor
development. The overall objective of this application is to develop a tolerogenic form of FVIII (TOLIP-FVIII) as
a novel immunotherapy to prevent inhibitor development in HA. This platform technology has been developed
with NHLBI support to PI that harnesses the tolerogenic property of our proprietary lysophosphatidylserine
(lysoPS) nanoparticle. We observed that an oral and intravenous (IV) pre-administration of FVIII associated with
lysoPS effectively reduced inhibitor development in naïve HA mice when challenged with free FVIII, suggesting
that FVIII-lysoPS (TOLIP-FVIII) is a tolerogenic form of FVIII that could prevent inhibitor development. As the
risk of inhibitor development is much higher during the first 20 exposures of FVIII, we envision this tolerogenic
form as beginner replacement therapy during high-risk exposure period, for previously untreated patients
(PUPs), to durably prevent inhibitor development. Further, due to improved plasma survival, this could also be a
longer acting FVIII for all HA patients. In R61 phase, we propose to (1) develop immunization protocol for durable
tolerance; (2) determine the half-life and hemostatic efficacy of IV administered TOLIP-FVIII by conducting
pharmacokinetic and pharmacodynamic studies in HA mice and (3) to investigate the toxicity of iv administered
TOLIP-FVIII in mice and in non-human primates. These SAs present measurable milestones, identification of
optimal immunization/treatment protocol for durable tolerance, non-inferior PK and hemostatic efficacy and
acceptable safety profile. As part of R33, in year 3, we will (1) investigate whether this TOLIP-FVIII approach
that is successful in HA mice can be translated to HA dogs and (2) characterize PK/PD of this tolerogenic form
of FVIII in HA dogs. Collaborations have been established with National Primate Center to investigate toxicity of
TOLIP-FVIII in non-human primates and with the University of North Carolina to conduct HA dog studies. We
propose a detailed project management plan and partnered with Empire Discovery Institute for R33 phase of the
project. Successful completion of the project will lead to a novel immunotherapy platform to prevent inhibitor
development in HA and could also lay the foundation for innovative therapeutic options with broad clinical
potential, such as prevention of immunogenicity of other therapeutic proteins, improve gene therapy and CRISPR
outcomes, and treat autoimmune conditions and allergies.
A 型血友病 (HA) 是由因子 VIII (FVIII) 缺乏或功能障碍引起的出血性疾病,因子 VIII (FVIII) 是一种重要的血友病。
凝血蛋白。使用外源性 FVIII 的替代疗法是一线疗法。然而,
这种挽救生命的疗法的一个主要临床并发症是中和性抗 FVIII 抗体的产生,
称为抑制剂,它会消除 FVIII 的生物活性并增加出血相关的风险
HA 患者的发病率和死亡率。目前抑制剂开发后的临床选择成本高昂(> 700,000 美元
每名患者每年),但对某些患者无效。因此,预防抑制剂的发展具有成本效益
在患者护理方面,但目前没有安全有效的预防疗法来避免抑制剂
发展。本申请的总体目标是开发一种耐受性形式的 FVIII (TOLIP-FVIII) 作为
一种预防 HA 抑制剂发展的新型免疫疗法。该平台技术已开发完成
借助 NHLBI 对 PI 的支持,利用我们专有的溶血磷脂酰丝氨酸的耐受性特性
(lysoPS)纳米颗粒。我们观察到,口服和静脉注射 (IV) 预给予 FVIII 与
当受到游离 FVIII 攻击时,lysoPS 有效减少了首次接触的 HA 小鼠中抑制剂的产生,表明
FVIII-lysoPS (TOLIP-FVIII) 是 FVIII 的一种耐受形式,可以阻止抑制剂的产生。作为
在前 20 次暴露于 FVIII 期间,产生抑制剂的风险要高得多,我们预计这种耐受性
对于以前未经治疗的患者,在高风险暴露期间作为初学者替代疗法
(PUP),持久防止抑制剂的发展。此外,由于血浆存活率提高,这也可能是
适用于所有 HA 患者的长效 FVIII。在R61阶段,我们建议(1)制定持久的免疫方案
宽容; (2)通过进行测定IV施用TOLIP-FVIII的半衰期和止血功效
HA 小鼠的药代动力学和药效学研究以及 (3) 研究静脉注射给药的毒性
TOLIP-FVIII 在小鼠和非人类灵长类动物中的作用。这些 SA 提出了可衡量的里程碑,确定了
最佳免疫/治疗方案,可实现持久耐受、不劣质的 PK 和止血功效以及
可接受的安全状况。作为 R33 的一部分,在第 3 年,我们将 (1) 研究这种 TOLIP-FVIII 方法是否
在 HA 小鼠中取得成功的结果可以转化为 HA 狗,并且 (2) 表征这种耐受形式的 PK/PD
HA 狗体内的 FVIII。已与国家灵长类动物中心建立合作,研究
TOLIP-FVIII 在非人类灵长类动物中的应用以及与北卡罗来纳大学合作进行的 HA 狗研究。我们
提出详细的项目管理计划,并与 Empire Discovery Institute 合作开展 R33 阶段的项目
项目。该项目的成功完成将产生一个新型的免疫治疗平台来预防抑制剂
HA 的发展也可以为具有广泛临床意义的创新治疗方案奠定基础
潜力,例如预防其他治疗蛋白的免疫原性,改善基因治疗和 CRISPR
结果,并治疗自身免疫性疾病和过敏。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SATHY VENKAT BALU-IYER其他文献
SATHY VENKAT BALU-IYER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SATHY VENKAT BALU-IYER', 18)}}的其他基金
Development and Pharmacology of Novel Lipidic rAHF
新型脂质rAHF的开发及药理学
- 批准号:
6872195 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
Development and Pharmacology of Novel Lipidic rAHF
新型脂质rAHF的开发及药理学
- 批准号:
6623164 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics
HL-新型脂质性 rAHF 和生物治疗药物的开发和药理学
- 批准号:
9198565 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
Development and Pharmacology of Novel Lipidic rAHF
新型脂质rAHF的开发及药理学
- 批准号:
6463657 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
Development and Pharmacology of Novel Lipidic rAHF
新型脂质rAHF的开发及药理学
- 批准号:
7196813 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
Development and Pharmacology of Novel Lipidic rAHF
新型脂质rAHF的开发及药理学
- 批准号:
7541330 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
Development and Pharmacology of Novel Lipidic rAHF
新型脂质rAHF的开发及药理学
- 批准号:
7341719 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
Development and pharmacology of novel lipidic rAHF
新型脂质rAHF的开发和药理学
- 批准号:
8471155 - 财政年份:2002
- 资助金额:
$ 57.55万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 57.55万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 57.55万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 57.55万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 57.55万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:














{{item.name}}会员




